Sanjivani Paranteral Ltd
Incorporated in 1994, Sanjivani Paranteral
Ltd does manufacturing and export of pharmaceutical products[1]
- Market Cap ₹ 266 Cr.
- Current Price ₹ 228
- High / Low ₹ 229 / 62.0
- Stock P/E 43.2
- Book Value ₹ 23.9
- Dividend Yield 0.00 %
- ROCE 55.3 %
- ROE 49.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 37.9% CAGR over last 5 years
Cons
- Stock is trading at 9.15 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -4.67%
- Promoter holding is low: 27.7%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
151.70 | 158.50 | 133.03 | 115.31 | 32.53 | 17.96 | 25.09 | 16.29 | 25.09 | 30.59 | 41.45 | 54.41 | |
141.11 | 148.93 | 127.71 | 120.84 | 55.81 | 70.17 | 26.85 | 16.62 | 22.95 | 24.86 | 35.80 | 46.18 | |
Operating Profit | 10.59 | 9.57 | 5.32 | -5.53 | -23.28 | -52.21 | -1.76 | -0.33 | 2.14 | 5.73 | 5.65 | 8.23 |
OPM % | 6.98% | 6.04% | 4.00% | -4.80% | -71.56% | -290.70% | -7.01% | -2.03% | 8.53% | 18.73% | 13.63% | 15.13% |
2.12 | 2.51 | 1.24 | 0.73 | 2.85 | 0.48 | 0.96 | 0.25 | 0.26 | 0.24 | 0.54 | 0.52 | |
Interest | 7.93 | 8.09 | 7.92 | 8.81 | 4.79 | 0.45 | 0.33 | 0.66 | 0.13 | 0.21 | 0.36 | 0.25 |
Depreciation | 0.99 | 0.95 | 1.41 | 1.36 | 1.20 | 1.19 | 1.17 | 1.07 | 0.86 | 0.88 | 0.89 | 0.93 |
Profit before tax | 3.79 | 3.04 | -2.77 | -14.97 | -26.42 | -53.37 | -2.30 | -1.81 | 1.41 | 4.88 | 4.94 | 7.57 |
Tax % | 36.15% | 47.37% | 13.00% | 2.20% | 0.72% | 0.60% | 10.00% | 5.52% | -0.71% | 0.61% | 8.70% | 18.63% |
2.43 | 1.59 | -2.41 | -14.64 | -26.22 | -53.06 | -2.07 | -1.71 | 1.42 | 4.85 | 4.51 | 6.17 | |
EPS in Rs | 4.12 | 2.70 | -4.09 | -24.82 | -44.45 | -89.96 | -3.51 | -2.90 | 1.67 | 4.85 | 4.51 | 5.28 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -10% |
5 Years: | 17% |
3 Years: | 29% |
TTM: | 31% |
Compounded Profit Growth | |
---|---|
10 Years: | 15% |
5 Years: | 38% |
3 Years: | 63% |
TTM: | 37% |
Stock Price CAGR | |
---|---|
10 Years: | 27% |
5 Years: | 94% |
3 Years: | 129% |
1 Year: | 236% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 50% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 8.50 | 10.00 | 10.00 | 11.68 |
Reserves | 27.52 | 29.11 | 26.24 | 11.60 | -14.62 | -58.72 | -53.10 | -54.81 | -53.39 | -17.58 | -13.07 | 16.21 |
57.39 | 56.90 | 57.06 | 62.20 | 59.89 | 48.23 | 48.09 | 48.91 | 46.05 | 6.00 | 2.49 | 0.97 | |
22.35 | 25.46 | 24.48 | 13.42 | 9.15 | 29.61 | 17.09 | 15.66 | 18.11 | 19.87 | 21.59 | 14.55 | |
Total Liabilities | 113.16 | 117.37 | 113.68 | 93.12 | 60.32 | 25.02 | 17.98 | 15.66 | 19.27 | 18.29 | 21.01 | 43.41 |
23.86 | 24.24 | 13.52 | 12.69 | 11.19 | 10.17 | 8.99 | 8.04 | 7.62 | 7.42 | 7.57 | 9.94 | |
CWIP | 0.07 | 0.07 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 |
89.18 | 93.01 | 100.10 | 80.38 | 49.08 | 14.80 | 8.94 | 7.57 | 11.60 | 10.82 | 13.39 | 33.47 | |
Total Assets | 113.16 | 117.37 | 113.68 | 93.12 | 60.32 | 25.02 | 17.98 | 15.66 | 19.27 | 18.29 | 21.01 | 43.41 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7.36 | 8.77 | -1.20 | 0.45 | 9.57 | 3.05 | 2.48 | -0.17 | 0.58 | 8.52 | 4.68 | -10.70 | |
-1.20 | -1.32 | 8.68 | -0.50 | 0.30 | -0.20 | 0.02 | -0.12 | -0.42 | -0.67 | -0.99 | -12.21 | |
-5.97 | -7.57 | -7.30 | -0.51 | -10.05 | -2.83 | -2.30 | 0.33 | -0.26 | -7.68 | -3.73 | 23.16 | |
Net Cash Flow | 0.19 | -0.12 | 0.18 | -0.57 | -0.18 | 0.03 | 0.20 | 0.03 | -0.09 | 0.17 | -0.04 | 0.24 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 142.01 | 149.34 | 184.24 | 151.59 | 358.38 | 107.71 | 75.79 | 23.97 | 96.45 | 58.71 | 17.52 | 31.53 |
Inventory Days | 50.08 | 54.73 | 68.59 | 65.35 | 127.41 | 34.08 | 13.56 | 66.80 | 22.43 | 51.89 | 105.21 | 124.70 |
Days Payable | 43.74 | 48.78 | 37.50 | 19.51 | 42.51 | 169.13 | 292.82 | 434.62 | 261.00 | 339.20 | 269.82 | 73.56 |
Cash Conversion Cycle | 148.35 | 155.29 | 215.34 | 197.43 | 443.28 | -27.33 | -203.47 | -343.84 | -142.12 | -228.61 | -147.08 | 82.67 |
Working Capital Days | 150.50 | 144.80 | 198.43 | 180.87 | 368.14 | -460.72 | -181.99 | -342.37 | -174.86 | -134.24 | -114.03 | 35.55 |
ROCE % | 13.02% | 12.18% | 5.95% | -7.31% | -35.52% | -227.18% | -258.43% | 265.52% |
Documents
Announcements
- Closure of Trading Window 27 Jun
- Announcement under Regulation 30 (LODR)-Change in Management 21 Jun
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 21 Jun
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 21 Jun
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Compliance Report as per Regulation 24 A of SEBI (LODR) Regulation , 2015 for the year ended on 31st March, 2024
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
Business Overview:
Sanjivani Paranteral Ltd is a pharmaceutical company headquartered in Mumbai. It specializes in manufacturing and distribution of high-quality parenteral and oral solid products. It caters to major therapeutic areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.[1]